Talmont Franck, Hatzoglou Anastassia, Cuvillier Olivier
Institut de pharmacologie et de biologie structurale, UMR 5089 CNRS, Université de Toulouse, 205 route de Narbonne, 31077 Toulouse, France.
Med Sci (Paris). 2020 Mar;36(3):243-252. doi: 10.1051/medsci/2020026. Epub 2020 Mar 31.
Multiple sclerosis (MS) is a disease of the central nervous system with a very debilitating inflammatory component that usually affects young people (years 20-40). This disease is characterized by the progressive destruction of the myelin sheath of the axons by the cells of the immune system, which results in neuronal degeneration. The T and B lymphocytes are the main players in this disease, which can be remittent with relapses or progressive. Among the drugs used to treat MS is the immunosuppressor fingolimod, the targets of which are the sphingosine 1-phosphate receptors. This molecule acts orally by preventing lymphocytes from leaving the thymus and lymph nodes and from reaching inflammatory brain foci. Other immunosuppressive drugs affecting sphingosine 1-phosphate receptors are under development and an intense search for curative drugs and treatments is being conducted.
多发性硬化症(MS)是一种中枢神经系统疾病,具有非常使人衰弱的炎症成分,通常影响年轻人(20至40岁)。这种疾病的特征是免疫系统细胞对轴突髓鞘进行性破坏,导致神经元变性。T淋巴细胞和B淋巴细胞是这种疾病的主要参与者,该病可以是缓解复发型或进行型。用于治疗MS的药物包括免疫抑制剂芬戈莫德,其靶点是1-磷酸鞘氨醇受体。该分子通过口服起作用,阻止淋巴细胞离开胸腺和淋巴结并到达脑部炎症病灶。其他影响1-磷酸鞘氨醇受体的免疫抑制药物正在研发中,并且正在大力寻找治愈性药物和治疗方法。